Clinical Trials

The purpose of this study is to describe the changes in cardiac Magnetic Resonance Elastography stiffness in Hypertrophic cardiomyopathy patients pre- and post-myectomy.

The purpose of this study is to use a survey to collect updated information on the clinical status of patients who have hypertrophic cardiomyopathy and are part of the ongoing database at Mayo Clinic.

The purpose of this study is to use magnetic resonance elastography to assess heart muscle stiffness in patients with hypertrophic cardiomyopathy compared to normal subjects.

The purpose of this study is:

• To ascertain the prevalence of major adverse cardiac events during pregnancy in patients with history of surgically corrected hypertrophic cardiomyopathy
• To determine the major adverse cardiac events (mortality, arrhythmias, hear failure, endocarditis, pulmonary embolism, myocardial infarction etc) in pregnant women after surgical correction of hypertrophic cardiomyopathy
   

The purpose of this study is to assess the long-term safety and tolerability of mavacamten in participants with hypertrophic cardiomyopathy (HCM) previously enrolled in 1 of 2 placebo-controlled trials: MAVERICK-HCM(MYK-461-006) or EXPLORER-HCM (MYK-461-005).

The purpose of this study is to evaluate the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy (oHCM [also known as HOCM]) who are eligible for SRT based on American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) and/or European Society of Cardiology (ESC) guidelines (i.e., guideline).

The purpose of this study is to

• Establish the long term functional capacity of patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

• Establish patients who do not improve symptomatically on long term follow up

• In patients, who do not have long term symptomatic improvement, ascertain predictors of poor outcomes.

This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2 target drug concentrations.

Previous work has shown that high sensitivity troponin levels are associated with degree of septal hypertrophy in hypertrophic cardiomyopathy. To further evaluate for the mechanisms of this association, we plan to reavaluate the septal pathology from myectomies in patients with HCM. Our hypothesis is that high sensitivity troponin (hs-TnT) and other biomarkers including NT-pro BNP will correlate with septal pathology in hypertrophic cardiomyopathy (HCM).

The purpose of this study is to:

1. Determine the structural accuracy of virtual three dimensional models of heart in patients with hypertrophic cardiomyopathy (HCM).

2. To explore the utility of virtual three dimensional modeling of heart in pre-operative planning of myectomy in patients with hypertrophic cardiomyopathy (HCM).

The purpose of this study is to evaluate the effectiveness and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction.

This study will evaluate the effect of GS-6615 on exercise capacity, quality of life, and safety and tolerability of GS-6615 in participants with symptomatic hypertrophic cardiomyopathy (HCM).

This study is aimed to describe the physiology that changes after operation for apical hypertrophic cardiomyopathy to explain symptom relief.

The purpose of this study is to evaluate the safety, tolerability, effectiveness, biological activity, and drug/body interactions of MYK-461 in adult patients who have symptomatic enlargement of the heart and obstruction of left ventricle outflow.

The purpose of this study is to use data mining methods to identify demographic, clinical, and new CMR, genetic and biomarker variables to then develop a predictive risk assessment model to score a patient's combination of factors for HCM, and establish the evidence base to later enable clinical trial design to reduce the morbidity and mortality of HCM in a cost-effective manner.

The purpose of this study is to establish initial safety, tolerability, drug/body interactions and biological activity of MYK-461 in people with an enlarged heart, or disease free controls.

This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will be randomized to receive placebo or mavacamten.

Exercise testing is routinely utilized in the evaluation of patient’s with hypertrophic cardiomyopathy to assess exercise capacity and also to evaluate the presence and severity of obstruction with an echocardiogram. Identifying significant obstruction is important in order to determine who could gain benefit from more invasive therapies like surgery.

There are several different exercise protocols available but it is not known which is the best method to assess the presence and severity of obstruction in hypertrophic cardiomyopathy. The purpose of this study is to determine which exercise protocol (supine bike or exercise treadmill) is better in these regards.

The primary purpose of this study is to assess the long-term safety and tolerability of mavacamten in participants with Hypertrophic Cardiomyopathy (HCM) previously enrolled in 1 of 2 placebo-controlled trials: MAVERICK-HCM for Non-obstructive (nHCM) and EXPLORER-HCM for Obstructive (oHCM).

The purpose of this study is to describe the clinical impact of cardiac rehabilitation in patients who have undergone myectomy for hypertrophic cardiomyopathy.  Compare the clinical outcomes of patients who have attended cardiac rehab with those who have not attended after myectomy for hypertrophic cardiomyopathy. 

This is a multicenter open-label study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM) who previously participated in study MYK-461-004 (PIONEER-HCM).

The purpose of this study is to determine prevalence of sleep apnea in patients with hypertrophic cardiomyopathy and assess cardiovascular risk markers.

The purpose of this study is to improve heart transplantation and clinical outcomes for transplant patients. The study will enroll individuals who are scheduled for heart surgery where samples from their heart will be collected as part of the normal surgical procedure.

Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.

The purpose of this study is to determine long term vital status, symptoms, and need for repeat procedure after alcohol septal ablation, to determine patient and procedural factors associated with successful alcohol septal ablation and need for repeat procedure, and to determine the impact of conduction abnormalities after alcohol septal ablation on long-term outcomes.

The purpose of this study is to determine how many patients suffer from sexual function problems and ascertain if they are improved or modified by cardiac surgical intervention.

This study is designed to identify genes shared between humans with hypertrophic cardiomyopathy and rhesus macaque primates who have experienced sudden cardiac death.

The primary purpose/objective of this study is to determine whether myectomy as a management option for severe hypertrophic cardiomyopathy (HCM) reduces the incidence of sudden cardiac death.

The goal is to determine how lifestyle and exercise impact the well-being of individuals with hypertrophic cardiomyopathy (HCM) and long QT syndrome (LQTS).

The purpose of this study is to determine prevalence of sleep apnea in patients with hypertrophic cardiomyopathy and the risk of atrial and ventricular arrhythmias.

The objective of this study is to determine the utility and accuracy of patients utilizing the About Me pedigree tool to create their own pedigrees for use in risk assessment in a cardiovascular genetics clinic. 

The aim of this study is to identify genes shared between humans and rhesus macaque primates who have been diagnosed with hypertrophic cardiomyopathy and have died suddenly.

The purpose of this study is to determine the incidence of atrial and ventricular arrhythmias in patients with hypertrophic cardiomyopathy, with and without sleep apnea.

The purpose of this study is to compare ejection hemodynamics in patients with obstructive hypertrophic cardiomyopathy (HCM) before and after septal myectomy.

This study is being done to determine whether or not new blood test(s) can determine the severity of heart conditions. Aortic stenosis, hypertrophic cardiomyopathy, mitral regurgitation, aortic regurgitation, artificial heart valve regurgitation or stenosis, and tricuspid valve regurgitation associated with pacemaker leads are the cardiac disorders under study. The blood tests involve analysis for von Willebrand Factor antigen and activity, von Willebrand Factor multimers, and brain natriuretic peptide (BNP) levels. The results of the blood tests will be compared to the information from the clinically-indicated echocardiogram and one blood test compared to another.

This study (SE2030) will establish a platform of data to build the perfect stress echo test, suitable for all patients, anywhere, anytime, also quantitative and operator independent.